Advanced in Undifferentiated Pleomorphic Sarcoma

Dr. Steven J. Dibiase

Radiation Oncology
Weill Medical College Of Cornell
5645 Main St, 
Flushing, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Advanced in Undifferentiated Pleomorphic Sarcoma
Weill Medical College Of Cornell
5645 Main St, 
Flushing, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Steven Dibiase is a Radiation Oncologist in Flushing, New York. Dr. Dibiase is rated as an Advanced provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Pleuropulmonary Blastoma, and Angiosarcoma of the Scalp. Dr. Dibiase is currently accepting new patients.

His clinical research consists of co-authoring 3 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiation Oncology
Licenses
Radiology in NJ
Hospital Affiliations
New York-Presbyterian/queens
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 2 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
5645 Main St, Flushing, NY 11355

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.
Enrollment Status: Recruiting
Publish Date: August 27, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 2
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Drug, Procedure, Other, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Bicalutamide, Buserelin, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Prednisone, Triptorelin
Study Phase: Phase 3
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Radiation
Study Phase: Not Applicable
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) : A Non-Inferiority Trial to Compare Breast Cosmesis and Local Control After Concomitant Boost Breast Radiotherapy With Fifteen Fractions in Three Weeks (Arm 1, Standard) Versus Ten Fractions in Two Weeks (Arm 2, Experimental)
Enrollment Status: Active_not_recruiting
Publish Date: July 25, 2025
Intervention Type: Radiation
Study Phase: Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: January 28, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + Intensity-modulated Radiation Therapy (IMRT) for Locally Advanced Non-Metastatic Squamous Cell Carcinoma (SCC) of the Oral Cavity/Oropharynx
Enrollment Status: Completed
Publish Date: September 20, 2021
Intervention Type: Radiation, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

3 Total Publications

Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States.
Regional Differences in the Treatment of Localized Prostate Cancer: An Analysis of Surgery and Radiation Utilization in the United States.
Journal: Advances in radiation oncology
Published: October 09, 2018
Similar Doctors
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Kaled M. Alektiar
Radiation Oncology
Distinguished in Undifferentiated Pleomorphic Sarcoma
Dr. Kaled M. Alektiar
Radiation Oncology

Memorial Radiation Oncology Group

1275 York Ave, 
New York, NY 
 (6.9 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kaled Alektiar is a Radiation Oncologist in New York, New York. Dr. Alektiar is rated as an Elite provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Endometrial Cancer, Adult Soft Tissue Sarcoma, Fibrosarcoma, Endometrial Stromal Sarcoma, and Lymphadenectomy.

Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Bhupesh Parashar
Radiation Oncology
Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Bhupesh Parashar
Radiation Oncology

North Shore-Lij Medical PC

27005 76th Ave, Suite 222, 
New Hyde Park, NY 
 (6.2 miles away)
718-470-7260
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Bhupesh Parashar is a Radiation Oncologist in New Hyde Park, New York. Dr. Parashar is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Laryngeal Cancer, Adult Soft Tissue Sarcoma, Lung Cancer, Pleuropulmonary Blastoma, and Gastrostomy.

Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Benjamin Cooper
Radiation Oncology
Advanced in Undifferentiated Pleomorphic Sarcoma
Dr. Benjamin Cooper
Radiation Oncology

New York University

560 1st Ave, 
New York, NY 
 (7.8 miles away)
212-263-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benjamin Cooper is a Radiation Oncologist in New York, New York. Dr. Cooper is rated as a Distinguished provider by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Squamous Cell Lung Carcinoma, and Lung Adenocarcinoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dibiase's expertise for a condition
ConditionClose
    View All 11 Advanced Conditions
    View All 35 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile